Foyston, Gordon, & Payne Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$16M |
| 2 |
Medtronic
MDT
|
+$6.22M |
| 3 |
Knowles
KN
|
+$4.68M |
| 4 |
Baxter International
BAX
|
+$4.2M |
| 5 |
Shinhan Financial Group
SHG
|
+$734K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$13.5M |
| 2 |
Ryder
R
|
+$5.64M |
| 3 |
ICICI Bank
IBN
|
+$4.68M |
| 4 |
Jabil
JBL
|
+$4.55M |
| 5 |
BHI
Baker Hughes
BHI
|
+$4.14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.58% |
| 2 | Technology | 15.83% |
| 3 | Financials | 15.07% |
| 4 | Energy | 11.76% |
| 5 | Consumer Staples | 9.77% |
Similar funds
Foyston, Gordon, & Payne's Q2 2014 Portfolio in Review
As of Q2 2014, Foyston, Gordon, & Payne held 86 positions worth $787M, down 3% from $812M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Foyston, Gordon, & Payne withdrew a net $58.4M in Q2 2014, closing 5 positions and reducing 49 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $13.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
Against the trend, Foyston, Gordon, & Payne opened a new position in Compañía de Cervecerías Unidas worth $693K.
- Foyston, Gordon, & Payne's largest Q2 2014 buy was Compañía de Cervecerías Unidas: 29,600 shares worth $693K.
- Foyston, Gordon, & Payne added most to Teva Pharmaceuticals in Q2 2014, an estimated $16M increase.
- Foyston, Gordon, & Payne's biggest Q2 2014 reduction was Ryder, cutting an estimated $5.64M.
- Foyston, Gordon, & Payne fully exited iShares Russell 2000 ETF in Q2 2014, selling an estimated $13.5M.
- Foyston, Gordon, & Payne's ten largest holdings make up 35% of its $787M portfolio in Q2 2014.
- Foyston, Gordon, & Payne opened 1 new position and closed 5 in Q2 2014.
- Foyston, Gordon, & Payne's portfolio value fell 3% quarter-over-quarter to $787M.
Based on Foyston, Gordon, & Payne's 13F filing for Q2 2014, filed 14 Aug 2014.